BREAKING NEWS : Hank Aaron, baseball legend and former home run king, dies at 86 Full Story

Gene therapy for rare retinal disorder to cost $425,000 per eye

A one-time treatment with Luxturna, the first US Food and Drug Administration-approved gene therapy for an inherited ...

Posted: Jan 4, 2018 9:16 AM
Updated: Jan 4, 2018 9:16 AM

A one-time treatment with Luxturna, the first US Food and Drug Administration-approved gene therapy for an inherited disorder, will cost $425,000 per eye.

Spark Therapeutics Inc., the Philadelphia-based maker of voretigene neparvovec, announced Wednesday in a statement that it reached an agreement in principle with Harvard Pilgrim and affiliates of-Express Scripts to make the one-time treatment available to patients with a rare genetic defect that often leads to blindness.

Luxturna, a one-time treatment, corrects a genetic mutation that can lead to blindness

Spark Therapeutics set the price for the gene therapy at $425,000 per eye

The mutation affects both eyes, usually at the same pace, so most patients would need treatment for both eyes, a Spark Therapeutics spokeswoman said.

In some cases, the gene therapy will be available under an "outcomes-based rebate arrangement." The company also stated that its proposal to the Centers for Medicare and Medicaid Services, the government program that covers about 100 million Americans, would allow installment payments for the drug.

"For a one-time therapy, like Luxturna, a non-traditional payment and distribution model is necessary to ensure needs of all parties -- patients, payers and providers -- are addressed," said Jennifer Luddy, a spokeswoman for Express Scripts.

At least one patient advocate disagrees.

"The new payment models announced today are merely a way to disguise a price that is simply too high," David Mitchell, president and founder of Patients For Affordable Drugs, said in a statement. "Spark Therapeutics is charging as much for Luxturna as they think they can get away with."

Spark Therapeutics CEO Jeff Marrazzo co-authored a recent blog post in the journal Health Affairs that said "the current payment system -- accustomed to ongoing treatment of chronic diseases -- creates significant challenges" for gene therapies and other treatments.

One-time-only treatments for rare genetic disorders are still unique, he noted.

The drug is intended for patients with retinal dystrophy due to a mutation of the RPE65 gene. This rare genetic defect causes severe visual impairment beginning in infancy and can eventually lead to blindness. The company believes the total "population in the US, Europe and select additional markets in the Americas and Asia/Pacific is up to approximately 6,000 individuals" who have the mutation targeted by Luxturna, explained Monique da Silva, a spokeswoman for Spark Therapeutics.

The drug will be available in the United States in early spring, with an estimated 1,000 to 2,000 people in the US standing to benefit from this treatment, according to Spark.

Luxturna is only the third gene therapy approved for use in the United States; two others were also approved in 2017. This is the first to correct an inherited genetic mutation.

Luxturna-is a liquid that is injected directly into the eye with a microscopic needle during a surgical procedure. The drug supplies a third gene -- a normal RPE65 gene -- to cells in the retina, a layer of tissue lining the back of the eye.-This third version of the gene does not remove or replace the two mutated genes causing the disease, which remain inside the cells. However, the normal gene delivered by the treatment is able to function within the retinal cells and correct vision problems.

In the phase 3 clinical trial, 27 out of 29 participants -- 93% -- who received the gene therapy demonstrated a gain in functional vision as assessed by a mobility test performed in a maze, according to the company. Risks of the treatment include cataracts, elevated eye pressure, retinal tears and holes and inflammation.

The company's offer of unusual payer models, including rebates and installment payments, will "help ensure patients' individual financial situation does not hinder access to treatment," da Silva said.

"New technologies such as gene and cell therapies hold out the potential to transform medicine," FDA Commissioner Dr. Scott Gottlieb-said in a statement announcing the August approval of Kymriah, considered to be the first gene therapy to be approved for the US market.

Kymriah is a leukemia treatment made by pharmaceutical giant Novartis. Similar to Luxturna, Kymriah is a one-time treatment, and its price tag is $475,000. However, Novartis said this price will not be charged to patients who do not respond within a month of treatment.

Indiana Coronavirus Cases

Data is updated nightly.

Cases: 601937

Reported Deaths: 9593
CountyCasesDeaths
Marion831111322
Lake44972678
Allen32498545
Hamilton29039315
St. Joseph27133380
Elkhart24291343
Vanderburgh19160246
Tippecanoe17799130
Johnson14871292
Porter14631167
Hendricks14188247
Madison10851219
Vigo10636178
Clark10520137
Monroe9299110
Delaware9055134
LaPorte8972160
Howard8134142
Kosciusko800382
Warrick665197
Hancock6575103
Bartholomew637999
Floyd6322109
Wayne6076161
Grant5937113
Dubois552578
Boone544967
Morgan530594
Henry503464
Marshall499884
Cass478663
Dearborn470745
Noble468357
Jackson420747
Shelby410781
Lawrence387478
Clinton370642
Gibson365559
DeKalb344264
Montgomery340754
Harrison340544
Knox333139
Miami317344
Steuben311545
Whitley301725
Wabash299747
Adams299035
Ripley296545
Putnam292049
Huntington288659
Jasper287634
White270340
Daviess266073
Jefferson257938
Fayette245148
Decatur244883
Greene238162
Posey236927
Wells233350
LaGrange226361
Scott221838
Clay220932
Randolph212148
Jennings195836
Sullivan190833
Spencer188019
Fountain182127
Washington182022
Starke174443
Jay166322
Owen162837
Fulton162330
Orange156333
Carroll155415
Rush153318
Perry151227
Vermillion147334
Franklin146933
Tipton130932
Parke13018
Pike115626
Blackford110522
Pulaski96137
Newton90521
Brown86833
Benton85910
Crawford7839
Martin72313
Warren6757
Switzerland6455
Union6227
Ohio4787
Unassigned0375

Ohio Coronavirus Cases

Data is updated nightly.

Cases: 849704

Reported Deaths: 10518
CountyCasesDeaths
Franklin100046706
Cuyahoga845231068
Hamilton63092447
Montgomery42660405
Summit34405754
Lucas31041611
Butler30546229
Stark25443429
Warren19436140
Lorain18767223
Mahoning17163337
Lake15882153
Clermont15697110
Delaware1422678
Licking13067137
Trumbull12680313
Fairfield1262180
Greene11915136
Medina11439167
Clark10802265
Wood10230158
Allen9774126
Portage9163107
Miami907373
Richland9035117
Marion7420113
Tuscarawas7280179
Columbiana7263124
Pickaway719550
Wayne6954169
Muskingum690741
Erie6090127
Hancock547590
Ross543487
Scioto533664
Geauga501155
Darke465591
Ashtabula449373
Lawrence447053
Union444928
Sandusky433062
Mercer432088
Huron423541
Seneca423465
Auglaize419662
Shelby419421
Jefferson415469
Belmont411240
Washington383340
Athens37379
Putnam372674
Madison349929
Knox347922
Ashland342538
Fulton335243
Defiance327782
Crawford319472
Preble318437
Brown307121
Logan304132
Ottawa289243
Clinton286643
Williams275866
Highland271818
Jackson261345
Guernsey249825
Champaign249328
Fayette234429
Morrow23014
Perry228318
Holmes222864
Henry216849
Hardin210133
Coshocton203521
Van Wert200545
Gallia194726
Wyandot193851
Pike172417
Adams172015
Hocking169824
Carroll153216
Paulding143221
Noble119940
Meigs106823
Monroe100331
Harrison87821
Morgan82229
Vinton68913
Unassigned00
Fort Wayne
Cloudy
26° wxIcon
Hi: 27° Lo: 26°
Feels Like: 16°
Angola
Cloudy
23° wxIcon
Hi: 24° Lo: 22°
Feels Like: 12°
Huntington
Cloudy
28° wxIcon
Hi: 26° Lo: 25°
Feels Like: 18°
Fort Wayne
Cloudy
26° wxIcon
Hi: 28° Lo: 27°
Feels Like: 16°
Lima
Cloudy
28° wxIcon
Hi: 29° Lo: 28°
Feels Like: 17°
Colder Friday
WFFT Radar
WFFT Temperatures
WFFT National

Community Events